Loading…

Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition

1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. in order to overcome this disadvantage, a new formulation, which combines Cu(II) and amant...

Full description

Saved in:
Bibliographic Details
Published in:Polyhedron 2020-07, Vol.185, p.114590, Article 114590
Main Authors: Banti, C.N., Kourkoumelis, N., Hatzidimitriou, A.G., Antoniadou, Ivi, Dimou, A., Rallis, M., Hoffmann, A., Schmidtke, M., McGuire, K., Busath, D., Kolocouris, A., Hadjikakou, S.K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43
cites cdi_FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43
container_end_page
container_issue
container_start_page 114590
container_title Polyhedron
container_volume 185
creator Banti, C.N.
Kourkoumelis, N.
Hatzidimitriou, A.G.
Antoniadou, Ivi
Dimou, A.
Rallis, M.
Hoffmann, A.
Schmidtke, M.
McGuire, K.
Busath, D.
Kolocouris, A.
Hadjikakou, S.K.
description 1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. in order to overcome this disadvantage, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one entity of formula {[AdNH3+]·[CuCl3]−}n, (CA) was developed. [Display omitted] •Copper(II) adamantanamines conjugates.•Mutations of influenza virus caused insensitivity to amantadine.•Blocking the proton current.•In vitro and vivo toxic toxicity effect. 1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. Thus, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one formula {[AdNH3+]·[CuCl3]−}, (CA) was developed. CA was characterized by m.p, conductivity measurements, FT-IR and UV–Vis spectroscopies, and X-ray crystallography. To the best of our knowledge the crystal and molecular structure of CA is the first one of amantadine with Cu(II) ions. CA was tested against the A/WSN/33 wt (M2 N31) virus and its mutations M2 S31N, M2 V27A, M2 L26F, M2 A30T and M2 G34E respectively. CA inhibits the wild virus A/WSN/33 wt-M2 N31, and its mutations -M2 S31N, -M2 L26F and -M2 A30T. The inhibition mechanism involves the increased membrane permeability of the CA, than free Cu(II) ions with simultaneous lower toxicity. CA acts by blocking the proton current of A/WSN/33-M2 S31N in a similar manner to Cu(II) ions. In silico studies confirmed that CA can effectively block proton current mediated by -M2 S31N virus replication. Specifically, [CuCl3]− blocks the primary gate of the His37 tetrad which is essential for channel conductance and selectivity. The in vitro toxicity of CA was examined against normal human fetal lung fibroblast (MRC-5) cells. No toxic effect was detected when the MRC-5 cells were treated by CA with concentrations up to 30 μΜ. The absence of micronucleus (MN) in MRC-5 cells treated CA (30 μΜ) confirms the in vitro non genotoxic behavior of the compound. Moreover, no any in vivo toxic effect was detected on Artemia salina upon their treatment with CA at a concentration up to 150 μΜ.
doi_str_mv 10.1016/j.poly.2020.114590
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1016_j_poly_2020_114590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0277538720302473</els_id><sourcerecordid>S0277538720302473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhvegYK3-AU971EPqfnYT8FKKH4GCFz0vm83ETsgXm7RSf70b6llmYJh35hmGl5A7zlac8fVjvRr65rQSTESBK52xC7JgwphEy9RcketxrFlcVFwuiN-0rptciR1Q3w8DhPs8f6B-3_QBy1nr6sOXm4B-47SnQz-OWDRAsR0aaCGiE_YdxTmr5gDdj6NHDIcx9nsscJ7ekMvKNSPc_tUl-Xx5_ti-Jbv313y72SVeMjYlotDMyBgqTYUWVaXW3mjBRVaUUvOscGklS5eBYz7LnPFKSuaV5kaptQMll0Sc7_oQ3wxQ2SFg68LJcmZna2xtZ2vsbI09WxOhpzME8bMjQrCjR-g8lBjAT7bs8T_8FwiAcHE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition</title><source>ScienceDirect Freedom Collection</source><creator>Banti, C.N. ; Kourkoumelis, N. ; Hatzidimitriou, A.G. ; Antoniadou, Ivi ; Dimou, A. ; Rallis, M. ; Hoffmann, A. ; Schmidtke, M. ; McGuire, K. ; Busath, D. ; Kolocouris, A. ; Hadjikakou, S.K.</creator><creatorcontrib>Banti, C.N. ; Kourkoumelis, N. ; Hatzidimitriou, A.G. ; Antoniadou, Ivi ; Dimou, A. ; Rallis, M. ; Hoffmann, A. ; Schmidtke, M. ; McGuire, K. ; Busath, D. ; Kolocouris, A. ; Hadjikakou, S.K.</creatorcontrib><description>1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. in order to overcome this disadvantage, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one entity of formula {[AdNH3+]·[CuCl3]−}n, (CA) was developed. [Display omitted] •Copper(II) adamantanamines conjugates.•Mutations of influenza virus caused insensitivity to amantadine.•Blocking the proton current.•In vitro and vivo toxic toxicity effect. 1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. Thus, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one formula {[AdNH3+]·[CuCl3]−}, (CA) was developed. CA was characterized by m.p, conductivity measurements, FT-IR and UV–Vis spectroscopies, and X-ray crystallography. To the best of our knowledge the crystal and molecular structure of CA is the first one of amantadine with Cu(II) ions. CA was tested against the A/WSN/33 wt (M2 N31) virus and its mutations M2 S31N, M2 V27A, M2 L26F, M2 A30T and M2 G34E respectively. CA inhibits the wild virus A/WSN/33 wt-M2 N31, and its mutations -M2 S31N, -M2 L26F and -M2 A30T. The inhibition mechanism involves the increased membrane permeability of the CA, than free Cu(II) ions with simultaneous lower toxicity. CA acts by blocking the proton current of A/WSN/33-M2 S31N in a similar manner to Cu(II) ions. In silico studies confirmed that CA can effectively block proton current mediated by -M2 S31N virus replication. Specifically, [CuCl3]− blocks the primary gate of the His37 tetrad which is essential for channel conductance and selectivity. The in vitro toxicity of CA was examined against normal human fetal lung fibroblast (MRC-5) cells. No toxic effect was detected when the MRC-5 cells were treated by CA with concentrations up to 30 μΜ. The absence of micronucleus (MN) in MRC-5 cells treated CA (30 μΜ) confirms the in vitro non genotoxic behavior of the compound. Moreover, no any in vivo toxic effect was detected on Artemia salina upon their treatment with CA at a concentration up to 150 μΜ.</description><identifier>ISSN: 0277-5387</identifier><identifier>DOI: 10.1016/j.poly.2020.114590</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Amantadine ; Amantadine-resistant A/WSN/33 M2 S31N mutation in influenza ; Biological Inorganic chemistry ; Copper(II) compound ; Crystal structure ; In silico study ; Metals in biology</subject><ispartof>Polyhedron, 2020-07, Vol.185, p.114590, Article 114590</ispartof><rights>2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43</citedby><cites>FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Banti, C.N.</creatorcontrib><creatorcontrib>Kourkoumelis, N.</creatorcontrib><creatorcontrib>Hatzidimitriou, A.G.</creatorcontrib><creatorcontrib>Antoniadou, Ivi</creatorcontrib><creatorcontrib>Dimou, A.</creatorcontrib><creatorcontrib>Rallis, M.</creatorcontrib><creatorcontrib>Hoffmann, A.</creatorcontrib><creatorcontrib>Schmidtke, M.</creatorcontrib><creatorcontrib>McGuire, K.</creatorcontrib><creatorcontrib>Busath, D.</creatorcontrib><creatorcontrib>Kolocouris, A.</creatorcontrib><creatorcontrib>Hadjikakou, S.K.</creatorcontrib><title>Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition</title><title>Polyhedron</title><description>1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. in order to overcome this disadvantage, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one entity of formula {[AdNH3+]·[CuCl3]−}n, (CA) was developed. [Display omitted] •Copper(II) adamantanamines conjugates.•Mutations of influenza virus caused insensitivity to amantadine.•Blocking the proton current.•In vitro and vivo toxic toxicity effect. 1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. Thus, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one formula {[AdNH3+]·[CuCl3]−}, (CA) was developed. CA was characterized by m.p, conductivity measurements, FT-IR and UV–Vis spectroscopies, and X-ray crystallography. To the best of our knowledge the crystal and molecular structure of CA is the first one of amantadine with Cu(II) ions. CA was tested against the A/WSN/33 wt (M2 N31) virus and its mutations M2 S31N, M2 V27A, M2 L26F, M2 A30T and M2 G34E respectively. CA inhibits the wild virus A/WSN/33 wt-M2 N31, and its mutations -M2 S31N, -M2 L26F and -M2 A30T. The inhibition mechanism involves the increased membrane permeability of the CA, than free Cu(II) ions with simultaneous lower toxicity. CA acts by blocking the proton current of A/WSN/33-M2 S31N in a similar manner to Cu(II) ions. In silico studies confirmed that CA can effectively block proton current mediated by -M2 S31N virus replication. Specifically, [CuCl3]− blocks the primary gate of the His37 tetrad which is essential for channel conductance and selectivity. The in vitro toxicity of CA was examined against normal human fetal lung fibroblast (MRC-5) cells. No toxic effect was detected when the MRC-5 cells were treated by CA with concentrations up to 30 μΜ. The absence of micronucleus (MN) in MRC-5 cells treated CA (30 μΜ) confirms the in vitro non genotoxic behavior of the compound. Moreover, no any in vivo toxic effect was detected on Artemia salina upon their treatment with CA at a concentration up to 150 μΜ.</description><subject>Amantadine</subject><subject>Amantadine-resistant A/WSN/33 M2 S31N mutation in influenza</subject><subject>Biological Inorganic chemistry</subject><subject>Copper(II) compound</subject><subject>Crystal structure</subject><subject>In silico study</subject><subject>Metals in biology</subject><issn>0277-5387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AQhvegYK3-AU971EPqfnYT8FKKH4GCFz0vm83ETsgXm7RSf70b6llmYJh35hmGl5A7zlac8fVjvRr65rQSTESBK52xC7JgwphEy9RcketxrFlcVFwuiN-0rptciR1Q3w8DhPs8f6B-3_QBy1nr6sOXm4B-47SnQz-OWDRAsR0aaCGiE_YdxTmr5gDdj6NHDIcx9nsscJ7ekMvKNSPc_tUl-Xx5_ti-Jbv313y72SVeMjYlotDMyBgqTYUWVaXW3mjBRVaUUvOscGklS5eBYz7LnPFKSuaV5kaptQMll0Sc7_oQ3wxQ2SFg68LJcmZna2xtZ2vsbI09WxOhpzME8bMjQrCjR-g8lBjAT7bs8T_8FwiAcHE</recordid><startdate>20200715</startdate><enddate>20200715</enddate><creator>Banti, C.N.</creator><creator>Kourkoumelis, N.</creator><creator>Hatzidimitriou, A.G.</creator><creator>Antoniadou, Ivi</creator><creator>Dimou, A.</creator><creator>Rallis, M.</creator><creator>Hoffmann, A.</creator><creator>Schmidtke, M.</creator><creator>McGuire, K.</creator><creator>Busath, D.</creator><creator>Kolocouris, A.</creator><creator>Hadjikakou, S.K.</creator><general>Elsevier Ltd</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200715</creationdate><title>Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition</title><author>Banti, C.N. ; Kourkoumelis, N. ; Hatzidimitriou, A.G. ; Antoniadou, Ivi ; Dimou, A. ; Rallis, M. ; Hoffmann, A. ; Schmidtke, M. ; McGuire, K. ; Busath, D. ; Kolocouris, A. ; Hadjikakou, S.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amantadine</topic><topic>Amantadine-resistant A/WSN/33 M2 S31N mutation in influenza</topic><topic>Biological Inorganic chemistry</topic><topic>Copper(II) compound</topic><topic>Crystal structure</topic><topic>In silico study</topic><topic>Metals in biology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banti, C.N.</creatorcontrib><creatorcontrib>Kourkoumelis, N.</creatorcontrib><creatorcontrib>Hatzidimitriou, A.G.</creatorcontrib><creatorcontrib>Antoniadou, Ivi</creatorcontrib><creatorcontrib>Dimou, A.</creatorcontrib><creatorcontrib>Rallis, M.</creatorcontrib><creatorcontrib>Hoffmann, A.</creatorcontrib><creatorcontrib>Schmidtke, M.</creatorcontrib><creatorcontrib>McGuire, K.</creatorcontrib><creatorcontrib>Busath, D.</creatorcontrib><creatorcontrib>Kolocouris, A.</creatorcontrib><creatorcontrib>Hadjikakou, S.K.</creatorcontrib><collection>CrossRef</collection><jtitle>Polyhedron</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Banti, C.N.</au><au>Kourkoumelis, N.</au><au>Hatzidimitriou, A.G.</au><au>Antoniadou, Ivi</au><au>Dimou, A.</au><au>Rallis, M.</au><au>Hoffmann, A.</au><au>Schmidtke, M.</au><au>McGuire, K.</au><au>Busath, D.</au><au>Kolocouris, A.</au><au>Hadjikakou, S.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition</atitle><jtitle>Polyhedron</jtitle><date>2020-07-15</date><risdate>2020</risdate><volume>185</volume><spage>114590</spage><pages>114590-</pages><artnum>114590</artnum><issn>0277-5387</issn><abstract>1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. in order to overcome this disadvantage, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one entity of formula {[AdNH3+]·[CuCl3]−}n, (CA) was developed. [Display omitted] •Copper(II) adamantanamines conjugates.•Mutations of influenza virus caused insensitivity to amantadine.•Blocking the proton current.•In vitro and vivo toxic toxicity effect. 1-Adamantanamine hydrochloride (AdNH3+ Cl−) is an antiviral drug that is used in the prophylactic or symptomatic treatment of influenza. However, a mutation makes influenza virus, amantadine (AdNH2) resistant. Thus, a new formulation, which combines Cu(II) and amantadine (AdNH2) in one formula {[AdNH3+]·[CuCl3]−}, (CA) was developed. CA was characterized by m.p, conductivity measurements, FT-IR and UV–Vis spectroscopies, and X-ray crystallography. To the best of our knowledge the crystal and molecular structure of CA is the first one of amantadine with Cu(II) ions. CA was tested against the A/WSN/33 wt (M2 N31) virus and its mutations M2 S31N, M2 V27A, M2 L26F, M2 A30T and M2 G34E respectively. CA inhibits the wild virus A/WSN/33 wt-M2 N31, and its mutations -M2 S31N, -M2 L26F and -M2 A30T. The inhibition mechanism involves the increased membrane permeability of the CA, than free Cu(II) ions with simultaneous lower toxicity. CA acts by blocking the proton current of A/WSN/33-M2 S31N in a similar manner to Cu(II) ions. In silico studies confirmed that CA can effectively block proton current mediated by -M2 S31N virus replication. Specifically, [CuCl3]− blocks the primary gate of the His37 tetrad which is essential for channel conductance and selectivity. The in vitro toxicity of CA was examined against normal human fetal lung fibroblast (MRC-5) cells. No toxic effect was detected when the MRC-5 cells were treated by CA with concentrations up to 30 μΜ. The absence of micronucleus (MN) in MRC-5 cells treated CA (30 μΜ) confirms the in vitro non genotoxic behavior of the compound. Moreover, no any in vivo toxic effect was detected on Artemia salina upon their treatment with CA at a concentration up to 150 μΜ.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.poly.2020.114590</doi></addata></record>
fulltext fulltext
identifier ISSN: 0277-5387
ispartof Polyhedron, 2020-07, Vol.185, p.114590, Article 114590
issn 0277-5387
language eng
recordid cdi_crossref_primary_10_1016_j_poly_2020_114590
source ScienceDirect Freedom Collection
subjects Amantadine
Amantadine-resistant A/WSN/33 M2 S31N mutation in influenza
Biological Inorganic chemistry
Copper(II) compound
Crystal structure
In silico study
Metals in biology
title Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A44%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amantadine%20copper(II)%20chloride%20conjugate%20with%20possible%20implementation%20in%20influenza%20virus%20inhibition&rft.jtitle=Polyhedron&rft.au=Banti,%20C.N.&rft.date=2020-07-15&rft.volume=185&rft.spage=114590&rft.pages=114590-&rft.artnum=114590&rft.issn=0277-5387&rft_id=info:doi/10.1016/j.poly.2020.114590&rft_dat=%3Celsevier_cross%3ES0277538720302473%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-2b5073737488252ff46c752129bd3519ba8f3da9ea0c99a7c4330c4517446ae43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true